Prospects for new restorative and neuroprotective treatments in Parkinson's disease

Stephen B. Dunnett and Anders Björklund
Additional contact information
Stephen B. Dunnett: Centre for Brain Repair, University of Cambridge, Forvie Site
Anders Björklund: Wallenberg Neuroscience Center, Lund University

Nature, 1999, vol. 399, issue 6738, A32-A39

Abstract: The degeneration of forebrain dopamine systems in Parkinson's disease has been an effective target for pharmaceutical research over the past four decades. However, although dopamine replacement may alleviate the symptoms of the disease, it does not halt the underlying neuronal degeneration. The past decade has seen major advances in identifying discrete genetic and molecular causes of parkinsonism and mapping the events involved in nigral cell death. This new understanding of the pathogenesis of the disease now offers novel prospects for therapy based on targeted neuroprotection of vulnerable neurons and effective strategies for their replacement.

Date: 1999
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/399a032 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:399:y:1999:i:6738:d:10.1038_399a032

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/399a032

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().